Asthma Section, ENT Section, Basic & Clinical Immunology Section
The increasing insight into the genetic, innate and adaptive mechanisms and their interaction with the environmental factors in asthma and allergic disease gives rise to targeted treatments. This master class will review and highlight important aspects and novel insights into the basic mechanisms and how they translate into the clinical presentation of (non) allergic asthma and rhinitis. In addition, novel targeted therapeutic options, including biologicals, anti-mediator drugs and immunomodulators, will be addressed while experience with these agents in clinical practice will be discussed in plenary sessions and workshops.
Expected Learning Outcomes:
We anticipate that the set up and the topics in this master class will broaden insights into the underlying mechanisms and the links to targeted therapeutic options for (non) allergic asthma and upper airway disease. The international exchange of clinical experience with these novel agents and discussions on potential future applications should create a platform to define unmet (research) needs.
So, attending this master class the participants will receive updates and gain insight into:
innate and adaptive basic mechanisms in asthma and rhinitis
the role of microbioma within upper and lower airways
the role of biomarkers, phenotypes, and endotypes in precision medicine of asthma and rhinitis available biologicals and their effectiveness in the treatment of asthma and rhinitis (which patients benefit from what biologicals?)
the role of allergen immunotherapy in the treatment of allergic asthma and rhinitis
potential novel therapeutic targets in asthma and rhinitis
how to apply targeted therapy in asthma and rhinitis through case reports and interactive sessions with experts
Whereas EAACI’s allergy schools are tailored for more junior attendees, master classes require a higher level of professional experience and offer an excellent platform for the exchange of knowledge. However, age is not a criterion for exclusion.
This master class is intended for clinicians, researchers and lab specialists who want to learn more about Treatments of Chronic Inflammatory Upper and Lower Airways Disease, focusing on Asthma and Rhinitis.
The EAACI Master Class on Biologicals Personalised Treatments of Chronic Inflammatory Upper and Lower Airways Disease: Biologicals, Immunomodulators and Other Targeted Therapeutics, Prague, Czech Republic, 13/04/2018-14/04/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 12 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
For more information regarding CME accreditation, please click here.
Submission of Case Reports:
This master class will include interactive case reports and plenary discussion sessions in which case reports submitted by attendees will be discussed. Case reports can now be submitted by email to email@example.com
Furthermore, the cases can be presented with or without slides and will be discussed with faculty and attendees.